Skip to main content
ZYUS Life Sciences Corporation logo

ZYUS Life Sciences Corporation — Investor Relations & Filings

Ticker · ZYUS ISIN · CA9899601095 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 299 across all filing types
Latest filing 2025-04-15 Director's Dealing
Country CA Canada
Listing TSXV ZYUS

About ZYUS Life Sciences Corporation

https://www.zyus.com/

ZYUS Life Sciences Corporation is a clinical-stage life sciences company dedicated to the development and commercialization of novel, non-opioid pharmaceutical drug candidates. The company focuses on proprietary cannabinoid-based therapeutics, or phyto-therapeutics, targeting the treatment of chronic and neuropathic pain. ZYUS's vision is to redefine the standard of care in pain management by developing evidence-based alternatives to conventional treatments, including opioids and NSAIDs. The core business involves advancing these drug product candidates through clinical trials, exemplified by the ongoing Phase 2a UTOPIA-1 trial evaluating a novel non-opioid pain drug.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Director's Dealing Classification · 85% confidence The document is an early warning news release under National Instrument 62-103 detailing a director’s acquisition of warrants and changes to his beneficial ownership. This constitutes insider share transactions by a company director, fitting the definition of Director’s Dealing (Code: DIRS).
2025-04-15 English
News release - English.pdf
Capital/Financing Update Classification · 90% confidence The document is a press release from Zyus Life Sciences announcing the issuance of bonus warrants in connection with loan amendments and extensions. It details financing activities (loan amendments, issuance of warrants, terms and conditions). This is not an earnings release, regulatory filing, or a general meeting announcement; instead it relates directly to capital/financing updates. Therefore, it falls under the "Capital/Financing Update" category (CAP).
2025-04-12 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a corporate press release announcing the amendment of a promissory note and the provision of additional loan financing along with warrant issuance. It details a related‐party loan agreement, principal amounts, maturity dates, interest rate, and capital usage. This is clearly an update on the company’s financing activities and capital structure rather than a management change, earnings release, or regulatory filing. It falls under ‘Capital/Financing Update’ (CAP).
2025-03-17 English
Material document(s).pdf
Capital/Financing Update Classification · 85% confidence The document is a formal loan amendment agreement between ZYUS Life Sciences and a lender, detailing changes to existing loan terms (maturity dates and conversion rights) and the issuance of warrants. This is clearly a financing transaction rather than a shareholder meeting notice, earnings release, regulatory filing announcement, or other category. Under the provided categories, it best fits “Capital/Financing Update” (Code: CAP) as it updates the company’s financing arrangements and capital structure.
2025-03-10 English
Material document(s).pdf
Capital/Financing Update Classification · 65% confidence The document is neither an annual, interim, audit, nor management report. It is a private loan agreement detailing debt terms (principal amount, interest rate, maturity) between the borrower and lender. This constitutes a financing arrangement and change in capital structure. Hence it falls under ‘Capital/Financing Update (CAP)’ rather than a report publication or regulatory notice.
2025-03-10 English
Material change report - English.pdf
Capital/Financing Update Classification · 85% confidence The document is a Canadian material change report (Form 51-102F3) announcing that an independent director advanced a CAD$1,500,000 unsecured loan to the company, amendments to prior unsecured loans, and the issuance of share purchase warrants. This is a detailed financing activity update (loan terms, interest, maturity, warrant issuance), fitting squarely under “Capital/Financing Update” (CAP). It is neither a short publication announcement nor a share issue notice exclusively—the substance is financing.
2025-03-10 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.